|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.22/-3.02
|
企业价值
2.74B
|
资产负债 |
每股账面净值
9.12
|
现金流量 |
现金流量率
--
|
损益表 |
收益
249.43M
|
每股收益
4.68
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 12:34 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. |